<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mitchell J</submitter><funding>Associazione Italiana per la Ricerca sul Cancro</funding><funding>Wellcome Trust</funding><pagination>323</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10796348</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find contamination across a range of cancer clinical indications and DNA sources, with highest prevalence in saliva samples from acute myeloid leukaemia patients, and sorted CD3+ T-cells from myeloproliferative neoplasms. Further exploration reveals 108 hotspot mutations in genes associated with haematological </pubmed_abstract><journal>Nature communications</journal><pubmed_title>Clinical application of tumour-in-normal contamination assessment from whole genome sequencing.</pubmed_title><pmcid>PMC10796348</pmcid><funding_grant_id>24913</funding_grant_id><pubmed_authors>Mitchell J</pubmed_authors><pubmed_authors>Bartram J</pubmed_authors><pubmed_authors>Yavorska O</pubmed_authors><pubmed_authors>Thomas R</pubmed_authors><pubmed_authors>Vago L</pubmed_authors><pubmed_authors>Caravagna G</pubmed_authors><pubmed_authors>Walker S</pubmed_authors><pubmed_authors>Volkova N</pubmed_authors><pubmed_authors>Zarowiecki M</pubmed_authors><pubmed_authors>Sosinsky A</pubmed_authors><pubmed_authors>Chalker J</pubmed_authors><pubmed_authors>Milite S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical application of tumour-in-normal contamination assessment from whole genome sequencing.</name><description>The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find contamination across a range of cancer clinical indications and DNA sources, with highest prevalence in saliva samples from acute myeloid leukaemia patients, and sorted CD3+ T-cells from myeloproliferative neoplasms. Further exploration reveals 108 hotspot mutations in genes associated with haematological </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan</publication><modification>2026-06-03T14:27:13.835Z</modification><creation>2025-04-04T19:22:23.016Z</creation></dates><accession>S-EPMC10796348</accession><cross_references><pubmed>38238294</pubmed><doi>10.1038/s41467-023-44158-2</doi></cross_references></HashMap>